These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 21926484

  • 21. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 22. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 23. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 24. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P, Legault M.
    Depress Anxiety; 2008 Oct 30; 25(12):E173-81. PubMed ID: 19006260
    [Abstract] [Full Text] [Related]

  • 25. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan 30; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 26. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Jan 30; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 27. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Jan 30; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 28. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
    Baldwin DS, Stein DJ, Dolberg OT, Bandelow B.
    Hum Psychopharmacol; 2009 Jun 30; 24(4):269-75. PubMed ID: 19334042
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM, Azorin JM, Despiegel N, Verpillat P.
    Int J Clin Pract; 2005 Mar 30; 59(3):268-75. PubMed ID: 15857321
    [Abstract] [Full Text] [Related]

  • 30. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
    Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M, Frisch A, Weizman A.
    J Child Adolesc Psychopharmacol; 2007 Dec 30; 17(6):741-50. PubMed ID: 18315446
    [Abstract] [Full Text] [Related]

  • 31. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.
    J Clin Psychiatry; 2011 Jul 30; 72(7):914-28. PubMed ID: 21208597
    [Abstract] [Full Text] [Related]

  • 32. An open-label, flexible-dose study of memantine in major depressive disorder.
    Ferguson JM, Shingleton RN.
    Clin Neuropharmacol; 2007 Jul 30; 30(3):136-44. PubMed ID: 17545748
    [Abstract] [Full Text] [Related]

  • 33. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
    Li H, Li T, Li G, Luo J.
    Ann Clin Psychiatry; 2014 Nov 30; 26(4):281-7. PubMed ID: 25401715
    [Abstract] [Full Text] [Related]

  • 34. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
    Salardini E, Zeinoddini A, Mohammadinejad P, Khodaie-Ardakani MR, Zahraei N, Zeinoddini A, Akhondzadeh S.
    J Psychiatr Res; 2016 Apr 30; 75():24-30. PubMed ID: 26800392
    [Abstract] [Full Text] [Related]

  • 35. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
    Bystritsky A, Kerwin L, Feusner JD, Vapnik T.
    Psychopharmacol Bull; 2008 Apr 30; 41(1):46-51. PubMed ID: 18362870
    [Abstract] [Full Text] [Related]

  • 36. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ.
    Acta Psychiatr Scand; 2012 Apr 30; 125(4):342-8. PubMed ID: 22077211
    [Abstract] [Full Text] [Related]

  • 37. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.
    Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M.
    J Child Adolesc Psychopharmacol; 2004 Apr 30; 14(2):175-84. PubMed ID: 15319015
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. High impact child abuse may predict risk of elevated suicidality during antidepressant initiation.
    Singh AB, Bousman CA, Ng CH, Berk M.
    Aust N Z J Psychiatry; 2013 Dec 30; 47(12):1191-5. PubMed ID: 24280998
    [Abstract] [Full Text] [Related]

  • 40. An open trial of citalopram in children and adolescents with depression.
    Shirazi E, Alaghband-Rad J.
    J Child Adolesc Psychopharmacol; 2005 Apr 30; 15(2):233-9. PubMed ID: 15910207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.